Qualitative Exploratory Study Among Reunionese Women and Their Partners Who Have a Child With Trisomy 21

Last updated: March 17, 2026
Sponsor: Centre Hospitalier Universitaire de la Réunion
Overall Status: Completed

Phase

N/A

Condition

Down's Syndrome

Treatment

Interview

Clinical Study ID

NCT04811534
2021/CHU/06
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

According to data from French congenital malformation registries, the prevalence of Down Syndrome (DS) in 2017 (live births and medical termination of pregnancy (MToP)) in Reunion Island was the lowest in France (23.04 per 10,000 births), notably in relation to a young maternal age. However, if we look at live births, Reunion Island has the highest prevalence of DS in France (12.24 vs. 5.81 per 10,000 births), despite a well organized prenatal diagnosis (PND). In fact, the use of MToP in this context is the lowest in France (10.8 vs 26.3 per 10 000 births).

Local specificities may have an impact on the choice of patients to undergo or not undergo a MToP in the context of PND of DS and explain why the rate of recourse to MToP is the lowest in France. To date, no qualitative study exploring the reasons why women and their partners do not undergo a MToP in the context of DS has been conducted in Reunion Island.

Thus, the main hypothesis is that the low recourse to MToP following PND of DS in Reunion Island could be explained by the beliefs, values or choices of Reunion Island women and their partners during pregnancy in relation to a specific family, socio-cultural and economic context.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Parents:

  • of a child born alive with Down Syndrome as of January 1, 2019 and registered withinREMACOR

  • living on the island of Reunion at the time of birth

  • having a good understanding of French and/or Creole

  • having given their written consent to the study

Exclusion

Exclusion Criteria:

Parents:

  • with normal/negative prenatal screening (False positive)

  • minors at the time of inclusion

  • under guardianship or legal protection

  • with a pathology preventing the interviews from taking place

Study Design

Total Participants: 28
Treatment Group(s): 1
Primary Treatment: Interview
Phase:
Study Start date:
February 28, 2022
Estimated Completion Date:
April 30, 2024

Connect with a study center

  • CHU de la Réunion

    Saint-Denis, 97400
    Reunion

    Site Not Available

  • CHU de la Réunion

    Saint-Pierre, 97448
    Reunion

    Site Not Available

  • CHU de la Réunion

    Saint-Denis, 97400
    Réunion

    Active - Recruiting

  • CHU de la Réunion

    Saint-Pierre, 97448
    Réunion

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.